superiority narrowly missed All-cause mortality: HR 0.86 (p=0.016, secondary analysis) LEADER Trial (Liraglutide)# The LEADER trial (Marso et al., NEJM 2016) enrolled 9,340 patients with T2D and high CV risk: Primary MACE: HR 0.87 (95% CI 0.78-0.97, p=0.01) CV death: HR 0.78 (22% reduction) All-cause mortality: HR 0.85 LEADER established liraglutide as the first GLP-1 agonist with proven cardiovascular superiority, a distinction exenatide did not achieve
doi: 10.1016/j.expneurol.2020.113178
Regular monthly scans allow the team to track progress with precision and adjust treatment plans in real time for consistently optimal results
For more information, see our list of foods to avoid on Semaglutide.
Medical supervision is recommended when using both
Another factor, connecting the intestine to brain pathways, is severe stress